canyon landscape

Study of Pamiparib in Newly Diagnosed and rGBM

This is an open-label, single-center Phase 0/2 study that will enroll up to 30 participants with newly diagnosed (N=12) and recurrent glioblastoma (N=18). The trial will be composed of a Phase 0 component (subdivided into Arm A, Arm B, and Arm C), and an Exploratory Phase 2 component. Participants with tumors demonstrating a PK response in the Phase 0 component of the study will graduate to an exploratory Phase 2 component that combines therapeutic dosing of pamiparib plus fractionated radiotherapy (for unmethylated MGMT promoter newly-diagnosed cases), pamiparib plus fractionated radiotherapy (for recurrent cases) or Olaparib plus fractionated radiotherapy (recurrent cases).

Status
Open and enrolling subjects.
Location
Phoenix, Arizona
Total Participants
30
Primary Sponsor
Nader Sanai, MD
Additional Sponsor(s)
Barrow Neurological Institute
Ivy Brain Tumor Center
BeiGene